Articles tagged with Myeloid Leukemia
Dr. John H. Bushweller's team at UVA Cancer Center is developing novel drugs to block abnormal proteins that cause pediatric leukemia. The new approach aims to improve efficacy and reduce toxicity, potentially leading to better patient outcomes.
Researchers found that resistance to leukemia treatment occurs due to rapid increase in mitochondria breakdown and turnover, allowing cells to evade death signals. A new combination of chloroquine and venetoclax restores the drug's ability to kill cancer cells by targeting a specific mitochondrial process.
A new method, CloneTracer, distinguishes between cancerous and healthy stem cells in acute myeloid leukemia (AML). The study reveals two distinct stem cell compartments and shows that progenitor cells respond better to therapy. This finding paves the way for developing new techniques to predict patient response to chemotherapy.
Researchers at The Mount Sinai Hospital have created versatile disease models of acute myeloid leukemia (AML), allowing for accurate study of the cancer's progression and response to drugs. These models, derived from induced pluripotent stem cells, can mimic different stages of AML and are nearly identical to those found in patients.
Acute myeloid leukemia is a cancer that affects blood cells and can lead to infection, anemia, and easy bleeding. The Georgia Cancer Center has received a $2.3 million grant to study how cancer cells resist treatment and propose new options to improve patient survival.
A new study reveals that targeting the SWI/SNF protein complex can disrupt PU-1-directed enhancer programs in AML cells, leading to therapeutic responses and rapid tumor regression. The findings also show that these inhibitors have manageable side effects on normal blood cells.
Scientists from USC Stem Cell laboratory discovered a mechanism linking leukemic mutations to varying disease potentials, identifying RNA splicing regulator Rbm25 as a critical factor. The study found that over-contributing clones of blood stem cells produce excessive myeloid cells, leading to potential leukemia development.
Researchers at German Cancer Research Center have developed a marker that predicts which patients with acute myeloid leukemia (AML) will respond to the new therapy. The marker, known as the MAC score, measures the ratio of specific proteins in leukemia stem cells and can be used to determine treatment success.
Researchers have identified two potential molecular targets, CSF1R and CD86, that can be used to develop CAR-T cells effective against acute myeloid leukemia. The study's findings demonstrate the potential of AI-assisted analysis in discovering new treatment options.
Children with Down syndrome are highly vulnerable to developing aggressive leukaemia due to a defect in the RUNX1 gene, which regulates blood cell formation. Researchers have identified a specific variant of the gene that promotes leukaemia development and discovered potential therapeutic approaches to correct this malfunction.
Researchers developed a blood test to detect residual leukemia in AML patients before bone marrow transplant, showing that those with persistent mutations had higher risks of relapse and lower survival rates. The study supports ongoing research on precision medicine and personalized post-transplant care.
A study published in CANCER found that children with acute lymphoblastic leukemia living along the US-Mexico border had a lower five-year survival rate compared to those in non-border areas. The research highlights existing disparities in pediatric cancer outcomes, particularly among Hispanic and Black communities.
A study published in Cell Reports found that a specific molecular cell program during foetal development can protect against acute myeloid leukaemia. The researchers used an experimental mouse model and discovered that the programme collides with the mechanism driving AML, explaining why leukaemia is rare in newborns.
Researchers at VCU Massey Cancer Center have discovered a novel combination therapy that dramatically suppresses the growth of AML cells, including those resistant to venetoclax. The dual mTORC1/2 inhibitors synergistically enhance AML cell death when paired with venetoclax.
Researchers evaluate an integrated NGS system, delivering accurate diagnoses in under 24 hours and expanding targeted treatments available to patients with myeloid neoplasms. The assay identified 80-92% of genetic variants, demonstrating promising results for accelerating precision therapies.
Pusan National University researchers have identified a novel gene, SURF4, that regulates cell death and differentiation in acute myeloid leukemia (AML). The study found that suppressing SURF4 expression increases cell differentiation, cell death, and accumulation of ROS, leading to arrested tumor growth in mice.
Researchers at NYU Langone Health developed an iScore system that correlates inflammation levels with survival rates in patients with acute myeloid leukemia (AML), with those having low scores surviving the longest.
Researchers at the University of Bergen have developed a method to predict cancer patient survival within hours of chemotherapy. By analyzing protein ERK1/2 levels in blood samples, they can identify patients who are responding or not responding to treatment, enabling early intervention.
A unique clinical trial has achieved a remarkable 97% induction survival rate in patients with acute promyelocytic leukemia (APL) by providing a simplified treatment regimen and 24/7 support from APL experts. This collaborative care model, known as EA9131, significantly reduced early deaths and improved overall survival rates.
Researchers have characterized the functional significance of DDX41 in molecular processes underlying cancer. The study reveals that DDX41 serves crucial functions in transcriptional processes, RNA splicing, and genomic integrity maintenance, which may hold significance in treating hematopoietic malignancies.
Researchers found that MK256 induced differentiation and maturation in leukemia stem cells, inhibiting proliferation of AML cell lines. The study also showed dose-dependent inhibition of the STAT pathway in both in vitro and in vivo studies.
The NCCN Annual Congress on Hematologic Malignancies will address key findings on chronic lymphocytic leukemia management and CAR T-cells in diffuse large B-cell lymphoma. The event also features updates on immunotherapies in multiple myeloma treatment.
Researchers have found that delivering a cellular metabolite via tiny particles called nanoliposomes can augment the beneficial effects of certain anti-leukemia drugs in models of acute myeloid leukemia. The study also uncovered several mechanisms behind these effects.
A study found that a majority of online pharmacies selling imatinib, a chronic myeloid leukemia therapy, are uncertified and operate unsafely. Patients may face risks of nonadherence, treatment failures, and adverse events if they use these pharmacies.
Researchers identified a unique metabolic adaptation in AML patients with FLT3-ITD+ mutations, using lactate as a substrate for mitochondrial respiration. This discovery could lead to customized therapies combining complex II inhibitors and MCT1 transporters.
A new study published in Blood Advances highlights significant inequities in diagnosis, treatment, and care between Black and white patients with acute myeloid leukemia (AML). Young adult Black patients were five times more likely to die within 30 days of beginning treatment compared to comparable white patients. The study also found c...
Researchers have discovered eight potential leukemia-killing compounds that target mitochondria, inducing mitophagy to weaken cancer cells. The compounds showed significant synergy with existing chemotherapy drugs, offering a deadly one-two punch against leukemia.
Researchers have developed a new therapeutic agent from Brazilian lapacho tree bark that targets acute myeloid leukemia cells while minimizing toxic effects on healthy cells. The compound is attached to an antibody that binds specifically to cancer cells, delivering the drug directly to its target.
A new cell therapy has been developed to target and eliminate leukemia stem cells that cause disease relapse. The treatment uses genetically engineered T cells with a chimeric antigen receptor that recognizes specific markers on these cancer cells.
Research found that hypomethylating agents (HMAs) activated the oncofetal protein SALL4 in up to 40% of patients with MDS, resulting in poor patient survival. This activation is linked to demethylation and upregulation of oncogenes, suggesting a need for additional combination therapy.
Research by University of Texas M.D. Anderson Cancer Center reveals adolescent and young adult leukemia survivors have shorter life spans than those without cancer. The study found inferior long-term mortality outcomes persist even decades after treatment, impacting quality of life and overall survival.
Adolescent and young adult leukemia survivors experience lower long-term survival compared to the general population, with age and sex influencing outcomes. Long-term mortality risks persist for up to 30 years after diagnosis, primarily due to late side effects from treatment.
Researchers have discovered a way to suppress a specific protein that promotes resistance to drugs commonly used to treat AML patients. This breakthrough has the potential to revolutionize treatment and prolong survival for those affected by the disease.
Researchers at Massachusetts General Hospital have developed a novel CAR T-cell construct that targets acute myeloid leukemia (AML) effectively. The combination of drug therapy and engineering approaches enhanced the treatment's ability to adhere to tumor cells, overcoming previous difficulties with antigen targeting.
A new study reveals a gene called KLF4 that normally suppresses tumor formation but is reprogrammed in acute promyelocytic leukemia, an aggressive type of blood cancer. Overexpressing KLF4 can suppress the growth of cancerous cells and reverse the effects of the disease.
Researchers at the University of Sussex have discovered a potential new target for treating acute myeloid leukaemia (AML) by understanding how two oncoproteins interact within cancer cells. The study found that beta-catenin and Wilms Tumour 1 proteins physically interact, impacting each other's oncogenic signalling activity.
A study reveals PDK1's crucial role in metabolic states of AML. Inhibition of PDK1 induces mitochondrial stress and improves antitumoral therapies.
Dr. John E. Dick will receive the inaugural AACR Award for Outstanding Achievement in Blood Cancer Research for his groundbreaking discoveries on leukemic stem cells and their mechanisms. His research has provided crucial insights into leukemia progression, survival rates, and treatment response.
Researchers at Cincinnati Children's Hospital Medical Center have identified a protein crucial to AML cell survival and found a small molecule that blocks its function, killing cancer cells in lab dishes and mouse models. This potential breakthrough could lead to novel therapies for AML and other conditions.
A study led by University of Illinois Chicago researchers found that structural racism can result in poorer leukemia outcomes for Black and Hispanic patients. Neighborhood disadvantage was a significant predictor of leukemia-specific death, accounting for nearly all the Black-white disparity in AML-related death.
Scientists at the Max Planck Institute of Biochemistry have discovered a new subtype of acute myeloid leukemia (AML) characterized by high amounts of mitochondrial proteins and altered mitochondrial metabolism. This subtype, called Mito-AML, shows clinical resistance to chemotherapy and can be effectively combated with inhibitors again...
Scientists have discovered a new subtype of relapsed pediatric AML characterized by a specific gene mutation called UBTF exon 13 tandem duplication (UBTF-TD), which is associated with poor outcomes and an increased incidence of minimal residual disease. This mutation can be used to identify high-risk patients and guide treatment.
Researchers identified a novel mutation in 9% of relapsed pediatric AML cases, suggesting a new subtype of the disease. The UBTF tandem duplication is associated with poor survival rates and higher likelihood of minimal residual disease positivity.
A UCLA researcher presented a groundbreaking case of an HIV-1 patient in remission after specialized stem cell transplantation for leukemia. The patient has been in remission for 4.5 years and has not experienced any HIV rebound since stopping antiretroviral therapy.
Researchers at Columbia University Irving Medical Center have found that targeting neighboring bone cells may be a better strategy than directly targeting blood cancer stem cells. By blocking the communication between leukemia cells and osteoblasts, the study suggests a new approach to treat acute myeloid leukemia.
Researchers at Cold Spring Harbor Laboratory discovered a previously unknown protein called SCP4 that plays a crucial role in the survival of acute myeloid leukemia cells. The study found that SCP4 can pair with specific kinases to regulate cell activity, and targeting this pathway may lead to effective treatment options.
A study published in Leukemia found that cord blood transplantation (CBT) was more effective than matched related donor transplantation (MRDT) for patients with refractory and relapsed acute myeloid leukemia (R/R AML). The study compared the survival rates of 1,738 CBT-treated patients with those of 713 MRDT-treated patients, revealing...
A team developed statistical models to predict the risk of early death in patients with non-intensive AML therapy. The models incorporated various health measures and quality-of-life scores, showing modest success in predicting outcomes.
Researchers at the University of Pennsylvania have discovered a new approach to triggering differentiation in AML cells, potentially treating a wider range of patients. By inhibiting an enzyme that blocks cellular differentiation, AML cells can lose aggressive growth traits and mature into new cell types.
A functional precision medicine study demonstrates that treatment selection based on results from drug sensitivity testing can be clinically useful in patients with aggressive hematological cancer. The approach combines deep molecular profiling with comprehensive drug sensitivity testing to advance the therapy decision-making system.
A recent study published in JNCCN found that only 31% of hospitals have immediate availability of all-trans retinoic acid (ATRA), a crucial blood cancer medication. This medication is essential for treating acute promyelocytic leukemia, which has a better prognosis when treated appropriately. The lack of ATRA availability poses a signi...
Researchers developed nanoTCEs to target AML cells, showing high specificity and potency in treating the disease. The technology uses nanoparticles to bind to CD33, a marker present on AML cells.
Research found that Pim kinase inhibitor co-treatment decreases alternative non-homologous end-joining DNA repair and genomic instability induced by topoisomerase 2 inhibitors in AML cells with FLT3-ITD. This approach may enhance chemotherapy drug induction of DNA DSBs and apoptosis.
Researchers discovered that acute myeloid leukemia (AML) depends on a transporter to bring in inositol, a sugar required for cells to survive. By blocking this transporter, cancer cells would starve without inositol. This method leaves normal cells unharmed as they can produce their own inositol.
Ulrich Steidl, a leading cancer researcher, has received an NCI grant to study the molecular mechanisms of myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). The goal is to develop new treatments and cures for these fatal disorders.
Researchers at Mount Sinai have developed a novel therapy called MS67 that effectively fights acute myeloid leukemia with mixed lineage leukemia rearrangement. The therapy degrades the WDR5 protein, which drives the proliferation of this type of leukemia and other cancers such as pancreatic cancer.
Researchers have identified a specific gene, RARA, associated with acute myeloid leukemia (AML) in children that is sensitive to the treatment tamibarotene. Studies found that AML cells with high levels of RARA are more responsive to tamibarotene, suggesting its potential as a new treatment for pediatric AML.
A new study has identified RNF5 as a key player in acute myeloid leukemia, regulating gene expression through its interaction with protein RBBP4. Inhibiting RNF5 may improve treatment outcomes for AML patients by increasing sensitivity to existing targeted therapies.
A phase II trial found that high-dose cytarabine followed by pembrolizumab improved cancer remission rates in AML patients, with a complete remission rate of 38%. The treatment also showed promise for patients who had not benefited from standard therapy.
A study by Cincinnati Children's Hospital Medical Center reveals that minor cells with mutations in the DDX41 gene can trigger a subset of inherited MDS cases. The research suggests that targeting these cells could lead to new treatment options for patients.